A plastid organelle as a drug target in apicomplexan parasites

被引:459
作者
Fichera, ME [1 ]
Roos, DS [1 ]
机构
[1] UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104
关键词
D O I
10.1038/37132
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Parasites of the phylum Apicomplexa include many important human and veterinary pathogens such as Plasmodium (malaria), Toxoplasma (a leading opportunistic infection associated with AIDS and congenital neurological birth defects), and Eimeria (an economically significant disease of poultry and cattle)(1-4). Recent studies have identified an unusual organelle in these parasites(5-7): a plastid that appears to have been acquired by secondary endosymbiosis of a green alga(7). Here ive show that replication of the apicomplexan plastid (apicoplast) genome in Toxoplasma gondii tachyzoites can be specifically inhibited using ciprofloxacin, and that this inhibition blocks parasite replication. Moreover, parasite death occurs with peculiar kinetics that are identical to those observed after exposure to clindamycin and macrolide antibiotics(8,9), which have been proposed to target protein synthesis in the apicoplast(9,10). Conversely, clindamycin (and functionally related compounds) immediately inhibits plastid replication upon drug application-the earliest effect so far described for these antibiotics. Our results directly link apicoplast function with parasite survival, validating this intriguing organelle as an effective target for parasiticidal drug design.
引用
收藏
页码:407 / 409
页数:3
相关论文
共 30 条
[1]   INVIVO ACTIVITY OF THE MACROLIDE ANTIBIOTICS AZITHROMYCIN, ROXITHROMYCIN AND SPIRAMYCIN AGAINST TOXOPLASMA-GONDII [J].
ARAUJO, FG ;
SHEPARD, RM ;
REMINGTON, JS .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (06) :519-524
[2]   INHIBITION OF CYTOPLASMIC AND ORGANELLAR PROTEIN-SYNTHESIS IN TOXOPLASMA-GONDII - IMPLICATIONS FOR THE TARGET OF MACROLIDE ANTIBIOTICS [J].
BECKERS, CJM ;
ROOS, DS ;
DONALD, RGK ;
LUFT, BJ ;
SCHWAB, JC ;
CAO, Y ;
JOINER, KA .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (01) :367-376
[3]  
*CDC, HLTH INF
[4]  
CUNDLIFFE E, 1990, RIBOSOME, P479
[5]   TREATMENT OF TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS - A RANDOMIZED TRIAL COMPARING PYRIMETHAMINE PLUS CLINDAMYCIN TO PYRIMETHAMINE PLUS SULFADIAZINE [J].
DANNEMANN, B ;
MCCUTCHAN, JA ;
ISRAELSKI, D ;
ANTONISKIS, D ;
LEPORT, C ;
LUFT, B ;
NUSSBAUM, J ;
CLUMECK, N ;
MORLAT, P ;
CHIU, J ;
VILDE, JL ;
ORELLANA, M ;
FEIGAL, D ;
BARTOK, A ;
HESELTINE, P ;
LEEDOM, J ;
REMINGTON, J .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :33-43
[6]   IN-VITRO ASSAYS ELUCIDATE PECULIAR KINETICS OF CLINDAMYCIN ACTION AGAINST TOXOPLASMA-GONDII [J].
FICHERA, ME ;
BHOPALE, MK ;
ROOS, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1530-1537
[7]   NEWLY DOCUMENTED ANTIMICROBIAL ACTIVITY OF QUINOLONES [J].
FURET, YX ;
PECHERE, JC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (04) :249-254
[8]   Chemotherapy of human and animal coccidioses: State and perspectives [J].
Haberkorn, A .
PARASITOLOGY RESEARCH, 1996, 82 (03) :193-199
[9]   Trovafloxacin is active against Toxoplasma gondii [J].
Khan, AA ;
Slifer, T ;
Araujo, FG ;
Remington, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1855-1859
[10]   GENE REPLACEMENT IN TOXOPLASMA-GONDII WITH CHLORAMPHENICOL ACETYLTRANSFERASE AS SELECTABLE MARKER [J].
KIM, K ;
SOLDATI, D ;
BOOTHROYD, JC .
SCIENCE, 1993, 262 (5135) :911-914